A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study(,)

PURPOSE: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Jandial, Danielle A., Brady, William E., Howell, Stephen B., Lankes, Heather A., Schilder, Russell J., Beumer, Jan H., Christner, Susan M., Strychor, Sandra, Powell, Matthew A., Hagemann, Andrea R., Moore, Kathleen N., Walker, Joan L., DiSilvestro, Paul A., Duska, Linda R., Fracasso, Paula M., Dizon, Don S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706109/
https://ncbi.nlm.nih.gov/pubmed/28341300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.03.013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados